This protocol will be used to collect crucial components of the immune system from healthy volunteers for the characterization of immune cells in fresh blood. A pipeline has been set up for comprehensive immune phenotyping of both lymphoid and myeloid cells within 24 hours after blood withdrawal.
Eligibility
Sex
ALL
Min age
36 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Age above 35 years
* Written informed consent
* No history of cancer
* No use of systemic immunosuppressive medication (eg. corticosteroids). Local use of corticosteroids (eg. topical or inhalation) is allowed.
Exclusion Criteria:
* Fever 14 days before blood withdrawal
* Donated blood for the same program within the last 2 years
* Pregnancy
Primary outcome measure(s)
The number of immune cells, both lymphoid and myeloid, present in the blood of healthy individuals, assessed by flow cytometry, as well as cytokine expression and transcriptome profiles of these cells — assessed up to 12 months the number of lymphoid and myeloid immune cells present in the blood of healthy individuals using flow cytometry, assessing the cytokine expression of these cells in healthy individuals using ELISA cytokine assays, and assessing gene expression of these cells using single cell transcriptomics analyses using droplet-based single cell RNA sequencing.
Trial sites (1)
Facility
City
Region
Status
NKI-AVL
Amsterdam
Netherlands
Recruiting
More The Netherlands Cancer Institute trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.